Home PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer’s disease or vascular dementia
Article
Licensed
Unlicensed Requires Authentication

PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer’s disease or vascular dementia

  • Carlo Cervellati EMAIL logo , Arianna Romani , Carlo M. Bergamini , Cristina Bosi , Juana Maria Sanz , Angelina Passaro and Giovanni Zuliani
Published/Copyright: December 9, 2014
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 53 Issue 7

Abstract

Background: A large body of evidence suggests that not only cerebral but also systemic oxidative stress (OxS) might be involved in the pathogenesis of late onset Alzheimer’s disease (LOAD) and vascular dementia (VAD), as well as of the prodromal phase of dementia, the so-called mild cognitive impairment (MCI). In the present study, we evaluated whether paraoxonase 1 (PON-1) and ferroxidase (FeOx) activities, because of their well acknowledged effectiveness as systemic antioxidants, might be associated with dementia and/or MCI.

Methods: Serum arylesterase and paraoxonase of PON-1, along with FeOx I (ceruloplasmin-related) and II activities were assessed in 223 MCI, 162 LOAD, 65 VAD patients, and in 143 older normal cognitive controls.

Results: Among the enzymatic activities examined, only arylesterase significantly changed across the groups (ANOVA: p<0.001), with similar lower levels in MCI, LOAD, and VAD compared to controls. By multivariate logistic regression analysis we showed that, in respect to controls, low levels (under the median value) of serum arylesterase were independently associated with an increase in the likelihood of being affected by LOAD [odds ratio (OR) 2.8, 95% confidence interval (CI) 1.5–5.0], VAD (OR 2.7, 95% CI 1.2–6.2), or MCI (OR 2.3, 95% CI 1.3–3.8).

Conclusions: Overall, our results suggest that depression of PON-1, and in particular, of arylesterase activity, in serum might be an early feature of dementia-related diseases. Further longitudinal exploration of the role of this enzyme in the onset and progression of these disorders are required.

Keywords: Alzheimer’s disease; ferroxidase; mild cognitive impairment; oxidative stress; paraoxonase-1; vascular dementia
Corresponding author: Carlo Cervellati, PhD, Department of Biochemistry and Molecular Biology, University of Ferrara, Via Luigi Borsari, 46, 44100, Ferrara, Italy, Phone: +39 3480399087, Fax: +39 0532 454442, E-mail: ; and Department of Biomedical and Specialist Surgical Sciences, Section of Medical Biochemistry, Molecular Biology and Genetics, University of Ferrara, Ferrara, Italy

Acknowledgments

The authors want to thank Monica Squerzanti and Eleonora Cremonini for their meaningful contribution in data collection and processing.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Financial support: The study was supported by ‘Local Research Project’ grant from University of Ferrara.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Praticò D. Evidence of oxidative stress in Alzheimer’s disease brain and antioxidant therapy. Ann NY Acad Sci 2008;1147:70–8.10.1196/annals.1427.010Search in Google Scholar

2. Zuliani G, Ranzini M, Guerra G, Rossi L, Munari MR, Zurlo A, et al. Plasma cytochines profile in older subject with late onset Alzheimer’s disease or vascular dementia. J Psychiatr Res 2007;41:686–93.10.1016/j.jpsychires.2006.02.008Search in Google Scholar

3. Candore G, Caruso C, Jirillo E, Magrone T, Vasto S. Low grade inflammation as a common pathogenetic denominator in age-related diseases: novel drug targets for anti-ageing strategies and successful ageing achievement. Curr Pharm Des 2010;16:584–96.10.2174/138161210790883868Search in Google Scholar

4. Smith MA, Zhu X, Tabaton M, Liu G, McKeel Jr DW, Nunomura MA, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 2010;19:363–72.10.3233/JAD-2010-1239Search in Google Scholar

5. Kaplan M, Aviram M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 1999;37:777–87.10.1515/CCLM.1999.118Search in Google Scholar

6. De la Torre JC. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004;3:184–90.10.1016/S1474-4422(04)00683-0Search in Google Scholar

7. Zhu X, Smith MA, Honda K, Aliev G, Moreira PI, Nunomura A, et al. Vascular oxidative stress in Alzheimer disease. J Neurol Sci 2007;257:240–6.10.1016/j.jns.2007.01.039Search in Google Scholar PubMed PubMed Central

8. Cervellati F, Cervellati C, Romani A, Cremonini E, Sticozzi C, Belmonte G, et al. Hypoxia induces cell damage via oxidative stress in retinal epithelial cells. Free Radic Res 2014;48:303–12.10.3109/10715762.2013.867484Search in Google Scholar PubMed

9. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010;49:1603–16.10.1016/j.freeradbiomed.2010.09.006Search in Google Scholar PubMed PubMed Central

10. Bergamini CM, Gambetti S, Dondi A, Cervellati C. Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 2004:10;1611–26.10.2174/1381612043384664Search in Google Scholar PubMed

11. Bartzokis G, Sultzer G, Cummings D, Holt J, Hance LE, Henderson DB, et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 2000;57:47–53.10.1001/archpsyc.57.1.47Search in Google Scholar PubMed

12. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: implications for early intervention and therapeutics. Biochim Biophys Acta 2011;1812:1359–70.10.1016/j.bbadis.2011.08.005Search in Google Scholar PubMed PubMed Central

13. Mondragón-Rodríguez S, Perry G, Zhu X, Moreira PI, Acevedo-Aquino MC, Williams S. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer’s disease. Oxid Med Cell Longev 2013;2013:940603.10.1155/2013/940603Search in Google Scholar PubMed PubMed Central

14. Cervellati C, Cremonini E, Bosi C, Magon S, Zurlo A, Bergamini CM, et al. Systemic oxidative stress in older patients with mild cognitive impairment or late onset Alzheimer’s disease. Curr Alzheimer Res 2013;10:365–72.10.2174/1567205011310040003Search in Google Scholar PubMed

15. Cervellati C, Romani A, Seripa D, Cremonini E, Bosi C, Magon S, et al. Oxidative balance, homocysteine, and uric acid levels in older patients with late onset Alzheimer’s disease or vascular dementia. J Neurol Sci 2014;337:156–61.10.1016/j.jns.2013.11.041Search in Google Scholar PubMed

16. Cervellati C, Romani A, Seripa D, Cremonini E, Bosi C, Magon S, et al. Systemic oxidative stress and conversion to dementia of elderly patients with mild cognitive impairment. Bio Med Res Int 2014;2014:309507.10.1155/2014/309507Search in Google Scholar PubMed PubMed Central

17. Gustaw-Rothenberg K, Kowalczuk K, Stryjecka-Zimmer M. Lipids’ peroxidation markers in Alzheimer’s disease and vascular dementia. Geriatr Geront Int 2010;10:161–6.Search in Google Scholar

18. Nguyen SD, Sok DE. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action. Free Radic Res 2003;37:1319–30.10.1080/5760310001621351-1Search in Google Scholar

19. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasic S, Spasojevic-Kalimanovska V, Topic A, et al. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 2007;37:715–22.10.1111/j.1365-2362.2007.01849.xSearch in Google Scholar PubMed

20. Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. J Am Med Assoc 2008;299:1265–76.10.1001/jama.299.11.1265Search in Google Scholar PubMed PubMed Central

21. Kotur-Stevuljevic J, Spasic S, Stefanovic A, Zeljkovic A, Bogavac-Stanojevic N, Kalimanovska-Ostric D, et al. Paraoxonase-1 (PON1) activity, but not PON1(Q192R) phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population. Clin Chem Lab Med 2006;44:1206–13.10.1515/CCLM.2006.216Search in Google Scholar PubMed

22. Martinelli N, Girelli D, Olivieri O, Guarini P, Bassi A, Trabetti E, et al. Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin Chem Lab Med 2009;47: 432–40.10.1515/CCLM.2009.108Search in Google Scholar PubMed

23. Jomova K, Valko M. Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr Pharm Des 2011;17:3460–73.10.2174/138161211798072463Search in Google Scholar PubMed

24. Erel O. Automated measurement of serum ferroxidase activity. Clin Chem 1998;44:2313–9.10.1093/clinchem/44.11.2313Search in Google Scholar

25. Qian ZM, Ke Y. Rethinking the role of ceruloplasmin in brain iron metabolism. Brain Res Rev 2011;35:287–94.Search in Google Scholar

26. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir A, Baldvinsson M, Johannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer’s disease. Dement Geriatr Cogn Dis 1998;9:239–42.10.1159/000017067Search in Google Scholar PubMed

27. Brewer G, Kanzer S, Zimmerman E, Celmins D, Heckman S, Dick R. Copper and ceruloplasmin abnormalities in Alzheimer’s disease Am. J Alzheimers Disord 2010;25:490–7.10.1177/1533317510375083Search in Google Scholar PubMed

28. Torsdottir G, Kristinsson J, Snaedal J, Johannesson T. Ceruloplasmin and iron proteins in the serum of patients with Alzheimer’s disease. Dement Geriatr Cogn Dis Extra 2011;1:366–71.10.1159/000330467Search in Google Scholar PubMed PubMed Central

29. Dantoine TF, Debord J, Merle L, Lacroix-Ramiandrisoa H, Bourzeix L, Charmes JP. Paraoxonase 1 activity: a new vascular marker of dementia? Ann NY Acad Sci 2002;977:96–101.10.1111/j.1749-6632.2002.tb04802.xSearch in Google Scholar PubMed

30. Wehr H, Bednarska-Makaruk M, Graban A, Lipczyńska-Łojkowska W, Rodo M, Bochyńska A, et al. Paraoxonase activity and dementia. J Neurol Sci 2009;283:107–8.10.1016/j.jns.2009.02.317Search in Google Scholar PubMed

31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.10.1212/WNL.34.7.939Search in Google Scholar PubMed

32. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–60.10.1212/WNL.43.2.250Search in Google Scholar PubMed

33. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–92.10.1001/archneur.58.12.1985Search in Google Scholar PubMed

34. La Du BN, Eckerson HW. The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed Proc 1984;43:2338–41.Search in Google Scholar

35. Zengi O, Karakas A, Ergun U, Senes M, Inan L, Yucel D. Urinary 8-hydroxy-2’-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer’s disease. Clin Chem Lab Med 2011;50:529–34.Search in Google Scholar

36. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006;52:601–23.10.1373/clinchem.2005.061408Search in Google Scholar PubMed

37. Marksbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 2005;58:730–5.10.1002/ana.20629Search in Google Scholar PubMed

38. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer’s disease. Ann Neurol 2002;52:175–9.10.1002/ana.10272Search in Google Scholar PubMed

39. Forman HJ, Davies KJ, Ursini F. How do nutritional antioxidants really work: Nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic Biol Med 2014;66:24–35.10.1016/j.freeradbiomed.2013.05.045Search in Google Scholar PubMed PubMed Central

40. Yildiz A, Gur M, Demirbag R, Yilmaz R, Akyol S, Aslan M, et al. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients. Clin Biochem 2008;41:779–84.10.1016/j.clinbiochem.2008.02.010Search in Google Scholar PubMed

41. Göçmen AY, Celikbilek A, Hacıoğlu G, Tanık N, Ağar A, Yargıcoğlu P, et al. The relationship between oxidative stress markers and visual evoked potentials in different hypertension models. Anadolu Kardiyol Derg 2014;14:498–504.10.5152/akd.2014.4923Search in Google Scholar PubMed

42. Uzun H, Karter Y, Aydin S, Curgunlu A, Simşek G, Yücel R, et al. Oxidative stress in white coat hypertension; role of paraoxonase. J Hum Hypertens 2004;18:523–8.10.1038/sj.jhh.1001697Search in Google Scholar PubMed

43. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am 2009;93:621–35.10.1016/j.mcna.2009.02.015Search in Google Scholar PubMed

44. Pi Y, Zhang L, Chang K, Li B, Guo L, Fang C, et al. Lack of an association between Paraoxonase 1 gene polymorphisms (Q192R, L55M) and Alzheimer’s disease: a meta-analysis. Neurosci Lett 2012;523:174–9.10.1016/j.neulet.2012.06.071Search in Google Scholar PubMed

45. Chapuis J, Boscher M, Bensemain F, Cottel D, Amouyel P, Lambert JC. Association study of the paraoxonase 1 gene with the risk of developing Alzheimer’s disease. Neurobiol Aging 2009:30;152–6.10.1016/j.neurobiolaging.2007.05.021Search in Google Scholar

46. Erlich PM, Lunetta KL, Cupples LA, Abraham CR, Green RC, Baldwin CT, et al. Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease. Neurobiol Aging 2012;33:1015.e7–23.10.1016/j.neurobiolaging.2010.08.003Search in Google Scholar

47. Camps J, Mackness M, Mackness B, Marsillach J, Joven J. Serum paraoxonase-1 activity and genetic polymorphisms: common errors in measurement and interpretation of results. Clin Chem Lab Med 2010;48:893–4.10.1515/CCLM.2010.156Search in Google Scholar

48. Leoni V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer’s disease. Clin Chem Lab Med 2011;49:375–83.10.1515/CCLM.2011.088Search in Google Scholar

49. Bednarska-Makaruk ME, Krzywkowski T, Graban A, Lipczyńska-Łojkowska W, Bochyńska A, Rodo M, et al. Paraoxonase 1 (PON1) gene-108c>T and p.Q192R polymorphisms and arylesterase activity of the enzyme in patients with dementia. Folia Neuropathol 2013;51:111–9.10.5114/fn.2013.35953Search in Google Scholar

50. Kim RH, Park JE, Park JW. Ceruloplasmin enhances DNA damage induced by hydrogen peroxide in vitro. Free Radic Res 2000;33:81–9.10.1080/10715760000300641Search in Google Scholar

51. Ehrenwald E, Chisolm GM, Fox PL. Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 1994;93:1493–501.10.1172/JCI117127Search in Google Scholar

52. Lamb DJ, Leake DS. Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein. FEBS Lett 1994;338:122–6.10.1016/0014-5793(94)80348-XSearch in Google Scholar

53. Androutsopoulos VP, Kanavouras K, Tsatsakis AM. Role of paraoxonase 1 (PON1) in organophosphate metabolism: implications in neurodegenerative diseases. Toxicol Appl Pharmacol 2011;256:418–24.10.1016/j.taap.2011.08.009Search in Google Scholar PubMed

Supplemental Material

The online version of this article (DOI: 10.1515/cclm-2014-0803) offers supplementary material, available to authorized users.

Received: 2014-8-8
Accepted: 2014-11-4
Published Online: 2014-12-9
Published in Print: 2015-6-1

©2015 by De Gruyter

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Personalized medicine: moving from simple theory to daily practice
  4. Evaluating and using innovative technologies: a lesson from Theranos?
  5. Review
  6. Emerging biomarkers in the detection and prognosis of prostate cancer
  7. Mini Review
  8. Could molecular assessment of calcium metabolism be a useful tool to early screen patients at risk for pre-eclampsia complicated pregnancy? Proposal and rationale
  9. Opinion Papers
  10. Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe
  11. Theranos phenomenon: promises and fallacies
  12. Clinical laboratories: production industry or medical services?
  13. Genetics and Molecular Diagnostics
  14. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms
  15. Direct identification of Gram-positive bacteria and resistance determinants from blood cultures using a microarray-based nucleic acid assay: in-depth analysis of microarray data for undetermined results
  16. General Clinical Chemistry and Laboratory Medicine
  17. Comparison between bottom-up and top-down approaches in the estimation of measurement uncertainty
  18. Role of vitamin D and sFlt-1/PlGF ratio in the development of early- and late-onset preeclampsia
  19. Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult
  20. PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer’s disease or vascular dementia
  21. Comparison of five automated hematology analyzers in a university hospital setting: Abbott Cell-Dyn Sapphire, Beckman Coulter DxH 800, Siemens Advia 2120i, Sysmex XE-5000, and Sysmex XN-2000
  22. Dacryocytes are a common morphologic feature of autoimmune and microangiopathic haemolytic anaemia
  23. Performance characteristics of a new automated method for measurement of anti-cyclic citrullinated peptide
  24. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method
  25. Reference Values and Biological Variations
  26. Reference interval for immature platelet fraction on Sysmex XN hematology analyzer: a comparison study with Sysmex XE-2100
  27. Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day
  28. Cancer Diagnostics
  29. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue
  30. Cardiovascular Diseases
  31. Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children
  32. Letters to the Editors
  33. Reporting of hemolysis index (HI) with laboratory results should be obligatory in newborns and infants
  34. Unmeasurably high chloride: a surrogate marker of thiocyanate poisoning identification
  35. Association between red cell distribution width and myocardial infarction in rheumatoid arthritis
  36. Plasmatic and urinary glycosaminoglycan profile in a patient affected by multiple sulfatase deficiency
  37. Rapid diagnosis of cryptococcal meningitis by Türk staining
  38. A high selectivity and sensitivity analytical method for the analysis of 8-hydroxy-2′-deoxyguanosine in the urine of Alzheimer’s disease patients
  39. S100B protein concentration measurement according to two different immunoassays
https://doi.org/10.1515/cclm-2014-0803
Keywords for this article
Alzheimer’s disease; ferroxidase; mild cognitive impairment; oxidative stress; paraoxonase-1; vascular dementia

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Personalized medicine: moving from simple theory to daily practice
  4. Evaluating and using innovative technologies: a lesson from Theranos?
  5. Review
  6. Emerging biomarkers in the detection and prognosis of prostate cancer
  7. Mini Review
  8. Could molecular assessment of calcium metabolism be a useful tool to early screen patients at risk for pre-eclampsia complicated pregnancy? Proposal and rationale
  9. Opinion Papers
  10. Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe
  11. Theranos phenomenon: promises and fallacies
  12. Clinical laboratories: production industry or medical services?
  13. Genetics and Molecular Diagnostics
  14. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms
  15. Direct identification of Gram-positive bacteria and resistance determinants from blood cultures using a microarray-based nucleic acid assay: in-depth analysis of microarray data for undetermined results
  16. General Clinical Chemistry and Laboratory Medicine
  17. Comparison between bottom-up and top-down approaches in the estimation of measurement uncertainty
  18. Role of vitamin D and sFlt-1/PlGF ratio in the development of early- and late-onset preeclampsia
  19. Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult
  20. PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer’s disease or vascular dementia
  21. Comparison of five automated hematology analyzers in a university hospital setting: Abbott Cell-Dyn Sapphire, Beckman Coulter DxH 800, Siemens Advia 2120i, Sysmex XE-5000, and Sysmex XN-2000
  22. Dacryocytes are a common morphologic feature of autoimmune and microangiopathic haemolytic anaemia
  23. Performance characteristics of a new automated method for measurement of anti-cyclic citrullinated peptide
  24. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method
  25. Reference Values and Biological Variations
  26. Reference interval for immature platelet fraction on Sysmex XN hematology analyzer: a comparison study with Sysmex XE-2100
  27. Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day
  28. Cancer Diagnostics
  29. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue
  30. Cardiovascular Diseases
  31. Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children
  32. Letters to the Editors
  33. Reporting of hemolysis index (HI) with laboratory results should be obligatory in newborns and infants
  34. Unmeasurably high chloride: a surrogate marker of thiocyanate poisoning identification
  35. Association between red cell distribution width and myocardial infarction in rheumatoid arthritis
  36. Plasmatic and urinary glycosaminoglycan profile in a patient affected by multiple sulfatase deficiency
  37. Rapid diagnosis of cryptococcal meningitis by Türk staining
  38. A high selectivity and sensitivity analytical method for the analysis of 8-hydroxy-2′-deoxyguanosine in the urine of Alzheimer’s disease patients
  39. S100B protein concentration measurement according to two different immunoassays
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 17.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2014-0803/html
Scroll to top button